347186-24-7

Usage

Phenylacetic acid derivative

It is a modified version of phenylacetic acid, with a piperazine moiety attached to it.

Piperazine moiety

A six-membered heterocyclic ring containing two nitrogen atoms, which is a key structural component of the compound.

Pharmaceutical intermediate

It is commonly used as a starting material in the synthesis of various drugs, particularly antipsychotic medications.

Potential as a ligand

2-(4-methylpiperazin-1-yl)-2-phenylacetic acid has been studied for its potential use as a ligand in the development of new coordination complexes.

Applications in chemistry and materials science

The compound's coordination complexes can have various applications in these fields, depending on their specific properties and uses.

Context-dependent properties and uses

The specific properties and applications of 2-(4-methylpiperazin-1-yl)-2-phenylacetic acid can vary depending on the context in which it is being used, such as the specific drug being synthesized or the intended application in coordination complexes.

Upstream product

• 1007877-82-8 benzyl 2-(4-methylpiperazin-1-yl)-2-phenylacetate 
• 62173-99-3 (S)-benzyl 2-hydroxy-2-phenylacetate 
• 1007877-81-7 benzyl 2-phenyl-2-(tosyloxy)acetate 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The present teachings provide a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Also described are a pharmaceutical composition and method of use thereof.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein A and B are each phenyl; D and E are each five-membered aromatic rings containing one, two, or three i hcteroatoms independently selected from nitrogen, oxygen, and sulfur; provided that ', at least one of D and E is other than imidazole; compositions and methods for the treatment of Hepatitis C virus (HCV) inf ection. Also disclosed are pharmaceutical compositions containing such compounds and methods f or using these compounds in the treatment of HCV inf ection.